Payer Considerations for Formulary Placement and Final Panelist Thoughts in MS and nrSPMS

In the final episode, Payer Considerations for Formulary Placement and Final Panelist Thoughts in MS and nrSPMS, the panelists explore the criteria payers use to determine formulary placement for current and emerging MS therapies, as well as final thoughts.

Payers rely on a range of clinical, economic, and real-world evidence to determine formulary placement for new multiple sclerosis (MS) and future non-relapsing secondary progressive MS (nrSPMS) therapies. Key criteria typically include demonstrated efficacy on clinically meaningful endpoints, safety and monitoring requirements, comparative effectiveness versus existing options, and overall budget impact. Increasingly, payers also consider real-world outcomes, patient adherence, and quality-of-life data when evaluating long-term value. As emerging therapies aim to address both inflammatory and neurodegenerative components of MS, formulary decision-making may evolve to weigh broader measures of disease modification, disability progression, and sustained functional outcomes, reshaping how value and treatment success are defined in MS care.

Led by the Jacquelyn Bainbridge, PharmD, FCCP, FAES, MSCS,, the neurology pharmacists examine the following critical questions:

What criteria do payers typically use to determine formulary placement for new MS and future nrSPMS therapies, and how might these criteria apply to agents that address both inflammatory and neurodegenerative components of the disease?

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this Pharmacy Times Peer Exchange series on multiple sclerosis. Please subscribe to our newsletter for information on upcoming video series.